Tekturna/Rasilez (aliskiren) from Novartis has failed to show a benefit in target organ protection which has resulted in the early...
The AQUARIUS study shows that Tekturna/Rasilez (aliskiren), from Novartis, neither improves nor slows the progression of coronary atherosclerosis when given...
Following the closure of the Phase III ALTITUDE trial, researchers have published the first detailed figures showing the risk of...
Novartis announced that the Tekturna labels have been updated in the USA, following the FDA review of the preliminary findings...